Literature DB >> 10708415

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

S Butrapet1, C Y Huang, D J Pierro, N Bhamarapravati, D J Gubler, R M Kinney.   

Abstract

The genome of a candidate dengue type 2 (DEN-2) vaccine virus, strain PDK-53, differs from its DEN-2 16681 parent by nine nucleotides. Using infectious cDNA clones, we constructed 18 recombinant 16681/PDK-53 viruses to analyze four 16681-to-PDK-53 mutations, including 5' noncoding region (5'NC)-57 C-to-T, premembrane (prM)-29 Asp-to-Val (the only mutation that occurs in the structural proteins), nonstructural protein 1 (NS1)-53 Gly-to-Asp, and NS3-250 Glu-to-Val. The viruses were studied for plaque size, growth rate, and temperature sensitivity in LLC-MK(2) cells, growth rate in C6/36 cells, and neurovirulence in newborn mice. All of the viruses replicated to peak titers of 10(7.3) PFU/ml or greater in LLC-MK(2) cells. The crippled replication of PDK-53 virus in C6/36 cells and its attenuation for mice were determined primarily by the 5'NC-57-T and NS1-53-Asp mutations. The temperature sensitivity of PDK-53 virus was attributed to the NS1-53-Asp and NS3-250-Val mutations. The 5'NC-57, NS1-53, and NS3-250 loci all contributed to the small-plaque phenotype of PDK-53 virus. Reversions at two or three of these loci in PDK-53 virus were required to reconstitute the phenotypic characteristics of the parental 16681 virus. The prM-29 locus had little or no effect on viral phenotype. Sequence analyses showed that PDK-53 virus is genetically identical to PDK-45 virus. Restriction of the three major genetic determinants of attenuation markers to nonstructural genomic regions makes the PDK-53 virus genotype attractive for the development of chimeric DEN virus vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708415      PMCID: PMC111799          DOI: 10.1128/jvi.74.7.3011-3019.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  From the World Health Organization. Development of dengue and Japanese encephalitis vaccines.

Authors:  W E Brandt
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

2.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.

Authors:  C J Lai; B T Zhao; H Hori; M Bray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

3.  Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.

Authors:  M M Khin; N Jirakanjanakit; S Yoksan; N Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  1994-12       Impact factor: 2.345

4.  Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.

Authors:  H Ni; G J Chang; H Xie; D W Trent; A D Barrett
Journal:  J Gen Virol       Date:  1995-02       Impact factor: 3.891

5.  Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

Authors:  T J Chambers; A Nestorowicz; P W Mason; C M Rice
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 6.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

7.  Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice.

Authors:  J X Cao; H Ni; M R Wills; G A Campbell; B K Sil; K D Ryman; I Kitchen; A D Barrett
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

8.  Mutagenesis of the yellow fever virus NS2B/3 cleavage site: determinants of cleavage site specificity and effects on polyprotein processing and viral replication.

Authors:  T J Chambers; A Nestorowicz; C M Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 9.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  THE TRANSMISSION OF NEUROTROPIC YELLOW FEVER VIRUS BY STEGOMYIA MOSQUITOES.

Authors:  N C Davis; W Lloyd; M Frobisher
Journal:  J Exp Med       Date:  1932-11-30       Impact factor: 14.307

View more
  61 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 4.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

5.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

6.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

7.  Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers.

Authors:  Richard M Kinney; Claire Y-H Huang; Becky C Rose; Andrew D Kroeker; Theo W Dreher; Patrick L Iversen; David A Stein
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Identification of genetic determinants of a tick-borne flavivirus associated with host-specific adaptation and pathogenicity.

Authors:  Dana N Mitzel; Sonja M Best; Max F Masnick; Stephen F Porcella; James B Wolfinbarger; Marshall E Bloom
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

10.  Characterization of recombinant dengue-2 virus derived from a single nucleotide substitution in the 5' noncoding region.

Authors:  Vijittra Leardkamolkarn; Wipawan Sirigulpanit; Richard M Kinney
Journal:  J Biomed Biotechnol       Date:  2010-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.